Literature DB >> 6437988

Human opsonins to meningococci after vaccination.

A Halstensen, B Haneberg, L O Frøholm, V Lehmann, C E Frasch, C O Solberg.   

Abstract

Two groups of volunteers were immunized with either a serogroup A plus C meningococcal polysaccharide vaccine or a combined serogroup B polysaccharide-serotype 2 protein vaccine. Serum opsonin responses were measured by chemiluminescence of polymorphonuclear leukocytes exposed to opsonized live meningococci. Two of the six volunteers immunized with the A plus C vaccine had an increase in serum opsonins to group A meningococci, four responded to group C meningococci, and none to group B meningococci. Five other volunteers who were immunized with the combined group B polysaccharide-serotype 2 protein vaccine responded with an increase in serum opsonins to group B meningococci of two different protein serotypes, as well as to a group C-serotype 2 meningococcal strain. Although no booster effect was observed after a second dose of the combined vaccine, both the polysaccharide and the protein components appear to be able to stimulate an opsonin response.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6437988      PMCID: PMC261595          DOI: 10.1128/iai.46.3.673-676.1984

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  Immunologic response of man to group B meningococcal polysaccharide vaccines.

Authors:  F A Wyle; M S Artenstein; B L Brandt; E C Tramont; D L Kasper; P L Altieri; S L Berman; J P Lowenthal
Journal:  J Infect Dis       Date:  1972-11       Impact factor: 5.226

2.  Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans.

Authors:  W D Zollinger; R E Mandrell; P Altieri; S Berman; J Lowenthal; M S Artenstein
Journal:  J Infect Dis       Date:  1978-06       Impact factor: 5.226

3.  Comparative immunogenicity of vaccines prepared from capsular polysaccharides of group C Neisseria meningitidis O-acetyl-positive and O-acetyl-negative variants and Escherichia coli K92 in adult volunteers.

Authors:  M P Glode; E B Lewin; A Sutton; C T Le; E C Gotschlich; J B Robbins
Journal:  J Infect Dis       Date:  1979-01       Impact factor: 5.226

4.  The relationship between group A and group C meningococcal polysaccharides and serum opsonins in man.

Authors:  R B Roberts
Journal:  J Exp Med       Date:  1970-03-01       Impact factor: 14.307

5.  Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70.

Authors:  R Gold; M S Artenstein
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

6.  Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.

Authors:  H Peltola; H Mäkelä; H Käyhty; H Jousimies; E Herva; K Hällström; A Sivonen; O V Renkonen; O Pettay; V Karanko; P Ahvonen; S Sarna
Journal:  N Engl J Med       Date:  1977-09-29       Impact factor: 91.245

7.  Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers.

Authors:  E C Gotschlich; I Goldschneider; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

8.  The interaction in vitro between group B meningococci and rabbit polymorphonuclear leukocytes. Demonstration of type specific opsonins and bactericidins.

Authors:  R B Roberts
Journal:  J Exp Med       Date:  1967-11-01       Impact factor: 14.307

9.  Protection against group B meningococcal disease. I. Comparison of group-specific and type-specific protection in the chick embryo model.

Authors:  C E Frasch; L Parkes; R M McNelis; E C Gotschlich
Journal:  J Exp Med       Date:  1976-08-01       Impact factor: 14.307

10.  Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.

Authors:  C E Frasch; J D Robbins
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

View more
  6 in total

1.  Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats.

Authors:  Maija Toropainen; Leena Saarinen; Gestur Vidarsson; Helena Käyhty
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Construction and functional activities of chimeric mouse-human immunoglobulin G and immunoglobulin M antibodies against the Neisseria meningitidis PorA P1.7 and P1.16 epitopes.

Authors:  Terje E Michaelsen; Øistein Ihle; Karen Johanne Beckstrøm; Tove K Herstad; Jan Kolberg; E Arne Høiby; Audun Aase
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

3.  Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine.

Authors:  A Aase; G Bjune; E A Høiby; E Rosenqvist; A K Pedersen; T E Michaelsen
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

4.  Opsonisation and phagocytosis of group B meningococci by polymorphonuclear leucocytes: comparison of sulphonamide sensitive and resistant strains.

Authors:  K N Ward; A Fleer; J Verhoef; D M Jones
Journal:  J Clin Pathol       Date:  1987-04       Impact factor: 3.411

Review 5.  Meningococcal lipopolysaccharides: virulence factor and potential vaccine component.

Authors:  A F Verheul; H Snippe; J T Poolman
Journal:  Microbiol Rev       Date:  1993-03

6.  Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants.

Authors:  A F Verheul; J A Van Gaans; E J Wiertz; H Snippe; J Verhoef; J T Poolman
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.